Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer

BJU International

Volumn 103, Issue 4, 2009, Pages 470-474

  Takayama, Hitoshi ^a   Nonomura, Norio ^a   Nishimura, Kazuo ^a   Oka, Daizo ^a   Shiba, Masahiro ^a   Nakai, Yasutomo ^a   Nakayama, Masashi ^a   Tsujimura, Akira ^a   Aozasa, Katsuyuki ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunohistochemical analysis; Macrophage scavenger receptor; Needle biopsy; Prognosis; Prostate cancer

Indexed keywords

ANTIANDROGEN; HORMONE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; SCAVENGER RECEPTOR;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; DNA POLYMORPHISM; GENE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MACROPHAGE; MACROPHAGE SCAVENGER RECEPTOR GENE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SOLID TUMOR;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, SCAVENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 59249099124     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08013.x     Document Type: Article

References (29)

1. Parkin DM, Whelan SL, Ferlay J et al. Cancer Incidence in Five Continents, Vol. 8. Lyon, France : IARC Scientific Publisher, 2002
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996 46 : 5 27
3. Dilloglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997 50 : 93 9
4. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 protatic adenocarcinoma-long-term results. J Urol 1990 144 : 1180 4
5. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991 145 : 907 23
6. Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999 17 : 222 72
7. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J Am Med Assoc 1997 277 : 1445 51
8. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? - The mouse's tale. J Clin Invest 2001 108 : 649 54
9. DeMarzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999 155 : 1985 92
10. Nelson WG, DeMarzo AM, DeWeese TL. The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology 2001 57 : 39 45
11. Xu J, Zheng SL, Komiya A et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002 32 : 321 5
12. Seppala EH, Ikonen T, Autio V et al. Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 2003 9 : 5252 6
13. Sun J, Hsu FC, Turner AR et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006 66 : 728 37
14. Pitas RE. Expression of the acetyl low-density-lipoprotein receptor by rabbit fibroblasts and smooth muscle cells: up-regulation by phorbol esters. J Biol Chem 1990 265 : 12722 7
15. Harshyne TM, Zimmer HI, Watkins SC, Barratt-Boyes SM. A role for class a scavenger receptor in dendritic cell nibbling from live cells. J Immunol 2003 170 : 2302 9
16. Yang G, Addai J, Tian W, Frolov A, Wheeler TM, Thompson TC. Reduced infiltration of class a scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res 2004 64 : 2076 82
17. Schroder FH, Hermanek P, Denis L et al. classification of prostate cancer. Prostate Suppl 1992 4 : 129 38
18. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974 111 : 58 64
19. de Villiers WJ, Fraser IP, Hughes DA, Doyle AG, Gordon S. Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function. J Exp Med 1994 180 : 705 9
20. de Villiers WJ, Fraser IP, Gordon S. Cytokine and growth factor regulation of macrophage scavenger receptor expression and function. Immunol Lett 1994 43 : 73 9
21. Geng Y, Hansson GK. Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte-derived macrophages. J Clin Invest 1992 89 : 1322 30
22. Mietus-Snyder M, Glass CK, Pitas RE. Transcriptional activation of scavenger receptor expression in human smooth muscle cells requires AP-1/c-Jun and C/EBPbeta: both AP-1 binding and JNK activation are induced by phorbol esters and oxidative stress. Arterioscler Thromb Vasc Biol 1998 18 : 1440 9
23. Nishimura N, Harada-Shiba M, Tajima S et al. Acquisition of secretion of transforming growth factor-β 1 leads to autonomous suppression of scavenger receptor activity in a monocyte-macrophage cell line, THP-1. J Biol Chem 1998 273 : 1562 7
24. Eastham JA, Truong LD, Rogers E et al. Transforming growth factor-â 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995 3 : 628 35
25. Wilstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor-β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998 37 : 19 29
26. Liao HS, Matsumoto A, Itakura H et al. Transcriptional inhibition by interleukin-6 of the class A macrophage scavenger receptor in macrophages derived from human peripheral monocytes and the THP-1 monocytic cell line. Arterioscler Thromb Vasc Biol 1999 19 : 1872 80
27. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999 161 : 182 7
28. Nakashima J, Tachibana M, Horiguchi Y et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000 6 : 2702 6
29. Geng YJ, Holm J, Nygren S, Bruzelius M, Stemme S, Hansson GK. Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon-gamma. Arterioscler Thromb Vasc Biol 1995 15 : 1995 2002